Display options
Cite
Farinha CM, Sousa M, Canato S, et al. Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect. 2015;3(4):e00152doi: 10.1002/prp2.152.
Farinha, C. M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., & Amaral, M. D. (2015). Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacology research & perspectives, 3(4), e00152. https://doi.org/10.1002/prp2.152
Farinha, Carlos M, et al. "Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR." Pharmacology research & perspectives vol. 3,4 (2015): e00152. doi: https://doi.org/10.1002/prp2.152
Farinha CM, Sousa M, Canato S, Schmidt A, Uliyakina I, Amaral MD. Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect. 2015 Aug;3(4):e00152. doi: 10.1002/prp2.152. Epub 2015 Jun 11. PMID: 26171232; PMCID: PMC4492728.
Copy Download .nbib Format: NLM
Share it on

Pharmacol Res Perspect. 2015 Aug;3(4):e00152. doi: 10.1002/prp2.152. Epub 2015 Jun 11.

Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR.

Pharmacology research & perspectives

Carlos M Farinha, Marisa Sousa, Sara Canato, André Schmidt, Inna Uliyakina, Margarida D Amaral

Affiliations

  1. University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute Campo Grande-C8, 1749-016, Lisboa, Portugal.

PMID: 26171232 PMCID: PMC4492728 DOI: 10.1002/prp2.152

Abstract

Cystic fibrosis (CF), the most common recessive autosomal disease among Caucasians, is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein. The most common mutation, F508del, leads to CFTR impaired plasma membrane trafficking. Therapies modulating CFTR basic defect are emerging, such as VX-809, a corrector of F508del-CFTR traffic which just succeeded in a Phase III clinical trial. We recently showed that VX-809 is additive to two other correctors (VRT-325 and compound 4a). Here, we aimed to determine whether the differential rescuing by these compounds results from cell-specific factors or rather from distinct effects at the early biogenesis and/or processing. The rescuing efficiencies of the above three correctors were first compared in different cellular models (primary respiratory cells, cystic fibrosis bronchial epithelial and baby hamster kidney [BHK] cell lines) by functional approaches: micro-Ussing chamber and iodide efflux. Next, biochemical methods (metabolic labeling, pulse-chase and immunoprecipitation) were used to determine their impact on CFTR biogenesis / processing. Functional analyses revealed that VX-809 has the greatest rescuing efficacy and that the relative efficiencies of the three compounds are essentially maintained in all three cellular models tested. Nevertheless, biochemical data show that VX-809 significantly stabilizes F508del-CFTR immature form, an effect that is not observed for C3 nor C4. VX-809 and C3 also significantly increase accumulation of immature CFTR. Our data suggest that VX-809 increases the stability of F508del-CFTR immature form at an early phase of its biogenesis, thus explaining its increased efficacy when inducing its rescue.

Keywords: CFTR function; CFTR modulators; Cellular systems; mechanism of action; novel therapies

References

  1. Biochemistry. 2009 Oct 20;48(41):9882-90 - PubMed
  2. Nat Chem Biol. 2013 Jul;9(7):444-54 - PubMed
  3. Mol Pharmacol. 2006 Jul;70(1):297-302 - PubMed
  4. Biochem J. 2002 Sep 15;366(Pt 3):797-806 - PubMed
  5. Science. 1989 Sep 8;245(4922):1066-73 - PubMed
  6. Sci Transl Med. 2014 Jul 23;6(246):246ra97 - PubMed
  7. Mol Cell Biol. 2005 Jun;25(12):5242-52 - PubMed
  8. Mol Biol Cell. 2013 Oct;24(19):3016-24 - PubMed
  9. J Mol Neurosci. 2004;23(1-2):41-8 - PubMed
  10. Mol Cell Probes. 2004 Aug;18(4):235-42 - PubMed
  11. Nature. 1992 Aug 27;358(6389):761-4 - PubMed
  12. Lancet Respir Med. 2014 Jul;2(7):527-38 - PubMed
  13. Curr Pharm Des. 2013;19(19):3497-508 - PubMed
  14. Am J Physiol Cell Physiol. 2010 Apr;298(4):C866-74 - PubMed
  15. J Physiol. 2005 Dec 1;569(Pt 2):601-15 - PubMed
  16. N Engl J Med. 2010 Nov 18;363(21):1991-2003 - PubMed
  17. Mol Pharmacol. 2005 May;67(5):1797-807 - PubMed
  18. Biochem J. 2007 Sep 1;406(2):257-63 - PubMed
  19. Mol Pharmacol. 2010 Sep;78(3):411-8 - PubMed
  20. Sci Transl Med. 2014 Jul 23;6(246):246ra96 - PubMed
  21. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8 - PubMed
  22. J Biol Chem. 2005 Nov 4;280(44):36762-72 - PubMed
  23. Mol Pharmacol. 2007 Mar;71(3):751-8 - PubMed
  24. Science. 1992 May 8;256(5058):774-9 - PubMed
  25. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17891-6 - PubMed
  26. Cell. 1995 Oct 6;83(1):129-35 - PubMed
  27. J Membr Biol. 1999 Jul 1;170(1):51-66 - PubMed
  28. Thorax. 2012 Jan;67(1):12-8 - PubMed
  29. Chem Biol. 2013 Jul 25;20(7):943-55 - PubMed
  30. J Clin Invest. 2005 Sep;115(9):2564-71 - PubMed
  31. J Cyst Fibros. 2014 Jul;13(4):363-72 - PubMed
  32. Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1117-30 - PubMed
  33. Biochem J. 2006 May 1;395(3):537-42 - PubMed
  34. J Biol Chem. 1996 Jan 12;271(2):635-8 - PubMed
  35. J Physiol. 1998 Nov 1;512 ( Pt 3):751-64 - PubMed
  36. Cold Spring Harb Perspect Biol. 2011 Feb 01;3(2):null - PubMed
  37. FASEB J. 2013 Feb;27(2):536-45 - PubMed
  38. Pulm Pharmacol Ther. 2010 Aug;23 (4):268-78 - PubMed
  39. J Cell Biol. 2004 Mar 15;164(6):923-33 - PubMed
  40. ACS Chem Biol. 2013 Feb 15;8(2):432-42 - PubMed
  41. Br J Pharmacol. 2013 Jan;168(1):253-65 - PubMed
  42. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30 - PubMed
  43. Chem Biol. 2014 May 22;21(5):666-78 - PubMed
  44. Cell. 1990 Nov 16;63(4):827-34 - PubMed

Publication Types